eligibility_summary
Include: age 1–70, R/R CD5+ T‑cell malignancy after or intolerant to standard therapy, ECOG 0–2, ≥60‑d survival, CD5+ by flow/IHC, auto CAR‑T: PB tumor <20% and off therapy >2 w, donor‑derived: allo‑HSCT donor available, willing for SCT at CR. Exclude: CNS disease, CHF/arrhythmia, severe respiratory failure, DIC, Cr/BUN ≥1.5×ULN, sepsis/active infection, uncontrolled diabetes, severe mental illness, prior non‑SCT transplant, pregnancy, hepatitis/HIV/syphilis+, post‑CAR‑T SCT infeasible, or no PBMC.
trial_source
clinical_trials.gov from Dec 2, 2025
annotation_status
ai
ai_summary
Intervention: CD5-targeted chimeric antigen receptor (CAR) T-cell therapy in three forms—autologous CD5 CAR T cells, prior stem-cell transplant donor–derived CD5 CAR T cells, and newly matched donor–derived CD5 CAR T cells. Type/mechanism: genetically engineered adoptive cellular immunotherapy, patient or donor T cells are modified to express an anti-CD5 CAR that binds CD5 on target cells and triggers T-cell activation (via CAR CD3ζ/costimulatory signaling) to mediate cytotoxic killing. Targets: CD5 antigen on malignant T cells in relapsed/refractory T-cell malignancies (e.g., T-ALL/LBL), on-target depletion of normal CD5+ T cells is expected. Pathways/cells engaged: CAR-T immune synapse formation and perforin/granzyme-mediated lysis of CD5+ lymphoblasts.